Engelmann S, Ebeling O, Schwartz-Albiez R
Tumor Immunology Program, German Cancer Research Center, Heidelberg.
Biochim Biophys Acta. 1995 May 29;1267(1):6-14. doi: 10.1016/0167-4889(95)00057-y.
Proteoglycans are mediators of cellular adhesion and regulate growth factor activities. Proteoglycans of B lymphocytes undergo structural changes during B cell ontogeny which may correspond to the specific requirements of the respective microenvironment of the maturing cell. We analyzed three human B cell lines representing pre-B cells (Nalm-6), activated B cells (Jok-1) and plasma cells (U266) for their cellular proteoglycans. Gel filtration of the 35S-labeled macromolecules of the three cell lines revealed an increase in size in the order Nalm-6 < Jok-1 < U266. In Jok-1 and U266 cells the major pool of proteoglycans consisted of proteochondroitin sulfates of 50 to 90 kDa. These proteolglycans carried a protein core of approx. 30 kDa to which 1 to 3 glycosaminoglycan chains in the range of 28 to 32 kDa were attached. In Nalm-6 cells only free chondroitin sulfate chains of 23 kDa, but no intact proteoglycans, were detected. Chondroitin sulfate chains were predominantly composed of chondroitin-4-sulfate, those of Nalm-6 and U266 cells additionally contained 10-20% of unsulfated disaccharides. In U266 cells 30% of glycosaminoglycans consisted of heparan sulfate either bound to pure proteoheparan sulfate or to chondroitin sulfate/heparan sulfate hybrid-proteoglycans. Earlier, syndecan-1 was described as a hybrid proteoglycan containing heparan sulfate/chondroitin sulfate chains which is transcribed by murine B cells at early and late maturation stages. In order to see whether syndecan is transcribed by the human B cell lines used here, we measured expression of syndecan mRNA by the reverse transcriptase polymerase chain reaction. Similar to murine lymphocytes, syndecan-specific mRNA was detected in Nalm-6 and U266 cells, equivalent to early and late B cells, but not in lymphoblastoid Jok-1 cells. However, Nalm-6 cells do not produce proteoheparan sulfate. In these cells, syndecan synthesis may be blocked at the translational level. Also, the proteoglycans of U266 are different from syndecan-1 in their composition of glycosaminoglycans and in size of protein cores. Together, these results indicate that the major pool of proteoglycans produced by human B cells consists of proteochondroitin sulfate and additionally in later stages of a smaller proportion of proteoheparan sulfate which is not identical to syndecan-1. During distinct phases of B cell differentiation, modulations in the glycosaminoglycan moiety concerning size and sulfation of glycosaminoglycan chains were also found.
蛋白聚糖是细胞黏附的介质,并调节生长因子活性。B淋巴细胞的蛋白聚糖在B细胞个体发育过程中会发生结构变化,这可能与成熟细胞各自微环境的特定需求相对应。我们分析了三种代表前B细胞(Nalm-6)、活化B细胞(Jok-1)和浆细胞(U266)的人B细胞系的细胞蛋白聚糖。对这三种细胞系的35S标记大分子进行凝胶过滤显示,其大小按Nalm-6 < Jok-1 < U266的顺序增加。在Jok-1和U266细胞中,蛋白聚糖的主要成分是50至90 kDa的硫酸软骨素蛋白聚糖。这些蛋白聚糖带有一个约30 kDa的蛋白核心,其上连接有1至3条28至32 kDa范围内的糖胺聚糖链。在Nalm-6细胞中,仅检测到23 kDa的游离硫酸软骨素链,未检测到完整的蛋白聚糖。硫酸软骨素链主要由硫酸软骨素-4-硫酸酯组成,Nalm-6和U266细胞的硫酸软骨素链还额外含有10 - 20%的非硫酸化二糖。在U266细胞中,30%的糖胺聚糖由硫酸乙酰肝素组成,其要么与纯硫酸乙酰肝素蛋白聚糖结合,要么与硫酸软骨素/硫酸乙酰肝素杂合蛋白聚糖结合。此前,syndecan-1被描述为一种含有硫酸乙酰肝素/硫酸软骨素链的杂合蛋白聚糖,在小鼠B细胞成熟的早期和晚期阶段都有转录。为了观察这里使用的人B细胞系是否转录syndecan,我们通过逆转录聚合酶链反应测量了syndecan mRNA的表达。与小鼠淋巴细胞类似,在相当于早期和晚期B细胞的Nalm-6和U266细胞中检测到了syndecan特异性mRNA,但在淋巴母细胞样Jok-1细胞中未检测到。然而,Nalm-6细胞不产生硫酸乙酰肝素蛋白聚糖。在这些细胞中,syndecan的合成可能在翻译水平受阻。此外,U266的蛋白聚糖在糖胺聚糖组成和蛋白核心大小方面与syndecan-1不同。总之,这些结果表明人B细胞产生的蛋白聚糖主要成分是硫酸软骨素蛋白聚糖,在后期还含有较小比例的硫酸乙酰肝素蛋白聚糖,且与syndecan-1不同。在B细胞分化的不同阶段,还发现了糖胺聚糖部分在糖胺聚糖链大小和硫酸化方面的调节。